Hikal Limited

Hikal Limited

Hikal Limited has announced its Q1 FY27 earnings conference call transcript, highlighting its recovery journey from a regulatory-led disruption last year to execution-led growth. The company reported revenue of Rs 403 crores with an EBITDA margin of 9.2% in Q1 FY27, driven by improving customer ordering patterns and product mix.

Hikal Limited

Hikal Limited has informed the Exchange about the newspaper publication of its unaudited financial results for Q1'FY27.

Hikal Limited

Hikal Limited has made available the audio recording of its earnings group conference call for the quarter ended June 30, 2026, on its website.

Hikal Limited

Hikal Limited announced its unaudited financial results for the quarter ended June 30, 2026, with revenue at Rs. 403 Crs and EBITDA margin expanding 260 bps YoY. The company's pharmaceutical business delivered revenue of Rs. 233 Cr in Q1FY27, growth of 15.2% YoY, while the crop protection business witnessed improved domestic demand in the Own Products segment.

Hikal Limited

Hikal Limited has informed the Exchange about the presentation of unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported revenue of ₹403 Cr. with an EBITDA margin of 9.2%. The Pharmaceutical business is in the penultimate stage of its remediation plan with the US FDA, while the Crop Protection business witnessed improved domestic demand in the Own Products segment.

Hikal Limited

Hikal Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, and the trading window for designated persons will reopen on August 9, 2026.

Hikal Limited

Hikal Limited has informed the Exchange about Schedule of meet for Q1 FY27 Post Results Conference Call on Thursday, 6th August 2026 at 05:00 PM (IST). The conference call will be attended by Mr. Sameer Hiremath, Vice Chairman and Managing Director, Mr. Anish Swadi, Senior President, Business Transformation and Animal Health, Mr. Kuldeep Jain, Chief Financial Officer, and Mr. Manoj Mehrotra, President, Pharmaceuticals Business.

Hikal Limited

Hikal Limited has been awarded the EcoVadis Gold Medal rating, placing it among the top 5% of more than 175,000 companies assessed globally by EcoVadis each year.

Hikal Limited

Hikal Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.

Hikal Limited

Hikal Limited has submitted a copy of the Scrutinizer's report of the Postal Ballot to the Exchange. The company has informed the Exchange regarding voting results. The Scrutinizer's Report and the voting results are being made available on the company's website.

Hikal Limited

Hikal Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, effective from July 01, 2026, till the expiry of 48 hours from the declaration of financial results for the quarter ending June 30, 2026.